The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients

scientific article published on 7 July 2005

The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1159/000086776
P698PubMed publication ID16015036
P5875ResearchGate publication ID7729736

P50authorRossana BerardiQ37378010
Roberto LabiancaQ39950156
Mario ScartozziQ42811548
P2093author name stringF Graziano
A Zaniboni
S Cascinu
A Sobrero
S Barni
G D Beretta
G Gasparini
V Catalano
Italian Group for the Study of Digestive Tract Cancer
P2860cites workNew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaQ27860904
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialQ28036747
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancerQ28364999
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupQ34511070
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancerQ36114988
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialQ39394495
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell lineQ41056508
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II studyQ44177866
P433issue2-3
P921main subjectcolorectal cancerQ188874
fluorouracilQ238512
irinotecanQ412197
oxaliplatinQ422327
P304page(s)212-216
P577publication date2005-07-07
P1433published inOncologyQ2016300
P1476titleThe role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
P478volume68

Reverse relations

cites work (P2860)
Q44644471Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis
Q46447739Healing of colonic anastomoses after immediate postoperative intraperitoneal administration of oxaliplatin
Q43136067The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin

Search more.